Co-Authors
This is a "connection" page, showing publications co-authored by Ignacio García-Doval and M Llamas-Velasco.
Connection Strength
0.688
-
Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study. Dermatol Ther. 2020 Nov; 33(6):e14170.
Score: 0.225
-
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Jul; 183(1):71-77.
Score: 0.222
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2021 Feb; 84(2):513-517.
Score: 0.057
-
Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016. Actas Dermosifiliogr (Engl Ed). 2018 Sep; 109(7):617-623.
Score: 0.048
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. J Am Acad Dermatol. 2018 04; 78(4):798-800.
Score: 0.046
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1700-1708.
Score: 0.045
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1021-1028.
Score: 0.044